Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090388 · ClinicalTrials.gov registry record
Bladder Cancer Patient-Reported Outcomes
A clinical trial of Bladder Neoplasms, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- 108
- Enrollment target
- 1
- Study location
NCT01090388 is a study of Bladder Neoplasms that has completed, run by Baylor College of Medicine. The registered enrollment target is 108 participants, below the 1,876-participant average among 3 other Bladder Neoplasms trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01090388, a study of Bladder Neoplasms, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify aspects of the bladder cancer (BlCa) survivorship experience that differ by clinical risk at diagnosis. The investigators will collect cross-sectional data from persons with BlCa to identify aspects of health-related quality of life (HRQOL) and symptom management. The study originally enrolled only nonmuscle-invasive bladder cancer survivors but has been expanded to include survivors with any stage disease. Information from this study will be used to develop a new patient education and counseling intervention.
Conditions Studied
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2007-07 |
| Est. Completion | 2016-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090388
The ClinicalTrials.gov registry entry for NCT01090388 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,876-participant average among 3 other Bladder Neoplasms trials with a reported enrollment target (94% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT01090388 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01090388 about?
NCT01090388 is a clinical study titled "Bladder Cancer Patient-Reported Outcomes". The purpose of this study is to identify aspects of the bladder cancer (BlCa) survivorship experience that differ by clinical risk at diagnosis. The investigators will collect cross-sectional data from persons with BlCa to identify aspects of health-related quality of life (HRQOL) and symptom manage...
What is the current status of trial NCT01090388?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2007-07. Estimated completion is 2016-11.
What conditions does trial NCT01090388 study?
This clinical trial studies the following conditions: Bladder Neoplasms.
Who is sponsoring clinical trial NCT01090388?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01090388 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.